A TALE‑based epigenetic editor produced durable therapeutic gene silencing after transient expression in non‑human primates, according to a Nature Biotechnology report. The approach used transcription activator‑like effector (TALE) machinery to deposit repressive chromatin marks, achieving long‑lasting suppression of target gene expression without permanent DNA cutting. Researchers demonstrated sustained effect in primate tissues, supporting translational potential for chronic diseases requiring prolonged target knockdown. The work addresses a key delivery and durability question for epigenetic therapies and provides a non‑cutting alternative to nuclease‑based gene editing, with potential safety advantages. For developers, TALE epigenetic editors offer a platform to induce persistent therapeutic effects from short‑lived delivery events—an attractive model for gene regulation in metabolic, neurologic or ophthalmic disorders.